Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
14h
GlobalData on MSNJ&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contractSamsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...
Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...
Walgreens said it had entered into a settlement agreement with telemedicine provider Everly Health Solutions as part of which ...
The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.
Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
5h
Chambersburg Public Opinion on MSNCentral Atlantic region gas prices slightly declined from last week: See how much hereHere's a look at how weekly regional gas prices changed in Central Atlantic region last week compared with the week prior.
On this week’s episode of “The Daily Show,” Jon Stewart accidentally sliced his hand open while smashing a coffee mug on his ...
Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results